11.1  0.57 (5.41%)		08-06 16:00
Open: 10.6 High: 11.475 Volume: 3,606,915		Pre. Close: 10.53 Low: 10.59 Market Cap: 688(M)

Short term
Mid term
Targets	6-month :	13.4	1-year :	15.65
Resists	First :	11.47	Second :	13.4
Pivot price	8.25
Supports	First :	7.94	Second :	5.76
MAs	MA(5) :	9.35	MA(20) :	7.87
	MA(100) :	5.6	MA(250) :	6.22
MACD	MACD :	1	Signal :	0.7
%K %D	K(14,3) :	95.5	D(3) :	89.8
RSI	RSI(14): 83.3
52-week	High :	11.47	Low :	3.75

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ HELP ] has closed above the upper band by 13.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 139.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	11.48 - 11.52	11.52 - 11.55
Low:	10.48 - 10.53	10.53 - 10.57
Close:	11.02 - 11.09	11.09 - 11.15

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

Thu, 06 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN

Sun, 02 Aug 2026
HELP Stock Price and Chart — NEO:HELP - TradingView

Tue, 21 Jul 2026
Crude Oil Surges 2%; 3M Shares Gain After Q2 Results - Sahm

Fri, 26 Jun 2026
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed? - Yahoo Finance

Thu, 25 Jun 2026
Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline - Stock Titan

Wed, 24 Jun 2026
Helus Pharma locks in US$50 million share sale, with results due in 2026 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	62 (M)
Shares Float	99 (M)
Held by Insiders	2.7 (%)
Held by Institutions	39.8 (%)
Shares Short	3,000 (K)
Shares Short P.Month	3,110 (K)

EPS	-4.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.05
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-41.4 %
Return on Equity (ttm)	-74.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.3
Qtrly Earnings Growth	0 %
Operating Cash Flow	-133 (M)
Levered Free Cash Flow	-83 (M)

PE Ratio	-2.62
PEG Ratio	0
Price to Book value	222
Price to Sales	0
Price to Cash Flow	-5.17

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.